Literature DB >> 28060562

Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.

Sarang Tartey1,2, Osamu Takeuchi1,2.   

Abstract

The innate immune system deploys a variety of pattern-recognition receptors (PRRs) which include Toll-like receptors (TLRs), RIG-I-like receptors, NOD-like receptors, and C-type lectin receptors to detect the invasion of pathogens and initiate protective responses. The intercellular and intracellular orchestration of signals from different PRRs, their endogenous or microbial ligands and accessory molecules determine the stimulatory or inhibitory responses. Progressing over the last two decades, considerable research on the molecular mechanisms underlying host-pathogen interactions has led to a paradigm shift of our understanding of TLR signaling in the innate immune system. Given that a significant amount of evidence implicates TLRs in the pathogenesis of immune diseases and cancer, and their activation occurs early in the inflammatory cascade, they are attractive targets for novel therapeutic agents. In this review, we discuss the recent advances in TLR signaling cross talks and the mechanism of pathogen recognition with special emphasis on the role of TLRs in tumor immunity and TLR-targeted therapeutics.

Entities:  

Keywords:  Pathogen recognition; TLR signaling; Toll like receptor; inflammation; therapeutics; tumor immunity

Mesh:

Substances:

Year:  2017        PMID: 28060562     DOI: 10.1080/08830185.2016.1261318

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  64 in total

Review 1.  GABAAR α2-activated neuroimmune signal controls binge drinking and impulsivity through regulation of the CCL2/CX3CL1 balance.

Authors:  Laure Aurelian; Irina Balan
Journal:  Psychopharmacology (Berl)       Date:  2019-04-27       Impact factor: 4.530

Review 2.  Inflammasomes in the pathophysiology of autoinflammatory syndromes.

Authors:  Sarang Tartey; Thirumala-Devi Kanneganti
Journal:  J Leukoc Biol       Date:  2019-10-14       Impact factor: 4.962

3.  PRRDB 2.0: a comprehensive database of pattern-recognition receptors and their ligands.

Authors:  Dilraj Kaur; Sumeet Patiyal; Neelam Sharma; Salman Sadullah Usmani; Gajendra P S Raghava
Journal:  Database (Oxford)       Date:  2019-01-01       Impact factor: 3.451

Review 4.  Activated neutrophils in the initiation and progression of COVID-19: hyperinflammation and immunothrombosis in COVID-19.

Authors:  Xinyi Zhao; Lijin Zhou; Yan Kou; Junjie Kou
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

5.  NF-κB mediates lipopolysaccharide-induced alternative pre-mRNA splicing of MyD88 in mouse macrophages.

Authors:  Frank Fang-Yao Lee; Kevin Davidson; Chelsea Harris; Jazalle McClendon; William J Janssen; Scott Alper
Journal:  J Biol Chem       Date:  2020-03-16       Impact factor: 5.157

6.  MiR-216a exerts tumor-suppressing functions in renal cell carcinoma by targeting TLR4.

Authors:  Wanhui Wang; Enyang Zhao; Yang Yu; Bo Geng; Wenfu Zhang; Xuedong Li
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

Review 7.  Differential role of the NLRP3 inflammasome in infection and tumorigenesis.

Authors:  Sarang Tartey; Thirumala-Devi Kanneganti
Journal:  Immunology       Date:  2019-02-14       Impact factor: 7.397

8.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

9.  Expression of Toll-like receptors 2 and 4 in the saliva of patients with systemic lupus erythematosus and chronic periodontitis.

Authors:  Consuelo P C Marques; Vandilson P Rodrigues; Larissa C de Carvalho; Louise P Nichilatti; Mayra M Franco; Fernando José B Patrício; Marcelo Magalhães; Marcelo S de Andrade; Bruno B Benatti
Journal:  Clin Rheumatol       Date:  2021-02-11       Impact factor: 2.980

10.  In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses.

Authors:  Matin Kayyal; Azam Bolhassani; Zahra Noormohammadi; Majid Sadeghizadeh
Journal:  Mol Biotechnol       Date:  2021-07-25       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.